摘要
索磷维伏是由3种不同靶点强效抗丙型肝炎病毒药物组成的复方片剂,其主要成分为索磷布韦、维帕他韦、伏西瑞韦。大量研究表明,该药不良反应少、疗效和耐受性良好,为直接抗病毒药物治疗失败的丙型病毒性肝炎患者提供了泛基因型、高治愈率的挽救治疗方案。本文就其药理作用及机制、药物代谢动力学、临床疗效评价、安全性评价等方面进行综述,旨在为其临床合理用药提供参考。
Sofosbuvir/Velpatasvir/Voxilaprevir is a compound tablet with three powerful anti-hepatitis C virus drugs(Sofosbuvir,Velpatasvir and Voxilaprevir)aimed at different targets.Many studies indicated it has fewer adverse reactions,higher curative effect and better tolerance.It provides a salvage therapy option with pan-genotype and high cure rate for patients with hepatitis C who failed in the treatment with direct-acting antiviral agents.This paper reviews the pharmacological action and mechanism,pharmacokinetics,clinical efficacy evaluation and safety evaluation of Sofosbuvir/Velpatasvir/Voxilaprevir,so as to provide references for its clinical rational use.
作者
姜晨晨
高峰
金鹏飞
JIANG Chen-chen;GAO Feng;JIN Peng-fei(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital),Beijing 100730,China;Department of Health Service,the Guard Bureau of the Joint Staff Department of Chinese PLA,Beijing 100017,China)
出处
《临床药物治疗杂志》
2021年第12期22-25,共4页
Clinical Medication Journal
关键词
索磷维伏
直接抗病毒药物
丙型肝炎病毒
作用机制
挽救治疗
Sofosbuvir/Velpatasvir/Voxilaprevir
direct-acting antiviral agent
hepatitis C virus
mechanism of action
salvage therapy
